Quoin Pharmaceuticals (QNRX) Set to Announce Earnings on Thursday

Quoin Pharmaceuticals (NASDAQ:QNRX) will likely be issuing its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect the company to announce earnings of ($1.5157) per share for the quarter. Interested persons can find conference call details on the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Thursday, November 5, 2026 at 9:30 AM ET.

Quoin Pharmaceuticals (NASDAQ:QNRX) last announced its earnings results on Friday, August 14th. The company reported ($1.90) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.61) by ($0.29).

Quoin Pharmaceuticals Stock Down 1.4%

QNRX opened at $3.96 on Wednesday. The stock’s 50 day moving average price is $5.37 and its 200-day moving average price is $6.03. Quoin Pharmaceuticals has a one year low of $3.25 and a one year high of $23.50.

Wall Street Analyst Weigh In

A number of research firms have weighed in on QNRX. Wall Street Zen upgraded Quoin Pharmaceuticals to a “sell” rating in a research note on Saturday, October 17th. Weiss Ratings reissued a “sell (e+)” rating on shares of Quoin Pharmaceuticals in a research note on Friday, October 16th. Lake Street Capital initiated coverage on shares of Quoin Pharmaceuticals in a report on Wednesday, September 23rd. They issued a “buy” rating and a $20.00 price target on the stock. Canaccord Genuity Group initiated coverage on shares of Quoin Pharmaceuticals in a report on Monday, October 19th. They issued a “buy” rating and a $18.00 price target on the stock. Finally, BTIG Research assumed coverage on shares of Quoin Pharmaceuticals in a research note on Monday, October 12th. They set a “buy” rating and a $14.00 price target for the company. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $17.33.

Insider Buying and Selling at Quoin Pharmaceuticals

In other Quoin Pharmaceuticals news, Director Anthony Culverwell acquired 6,146 shares of the business’s stock in a transaction that occurred on Monday, August 31st. The shares were bought at an average cost of $4.88 per share, with a total value of $29,992.48. Following the completion of the acquisition, the director directly owned 40,364 shares in the company, valued at $196,976.32. This represents a 17.96% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Denise P. Carter acquired 20,490 shares of Quoin Pharmaceuticals stock in a transaction that occurred on Monday, August 31st. The stock was acquired at an average cost of $4.88 per share, with a total value of $99,991.20. Following the purchase, the chief operating officer directly owned 37,709 shares of the company’s stock, valued at $184,019.92. This represents a 119.00% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last quarter, insiders acquired 57,370 shares of company stock worth $279,966. Company insiders own 7.54% of the company’s stock.

Quoin Pharmaceuticals Company Profile

Quoin Pharmaceuticals, Ltd. is a clinical-stage specialty pharmaceutical company focused on developing treatments for rare and orphan diseases. The company is primarily pursuing therapies for conditions with significant unmet medical needs, including rare genetic disorders affecting the skin.

Quoin’s lead program is QRX003, a topical lotion being developed for Netherton syndrome, a rare inherited skin disorder associated with impaired skin-barrier function. The company is also developing QRX004, a topical product candidate intended for recessive dystrophic epidermolysis bullosa, a severe genetic skin disease.